Introduction
Triple-negative breast cancer is defined by absent expression of the estrogen receptor [ER], progesterone receptor [PR] , and the human epidermal growth factor receptor 2 [HER2] negative status [1] . Given the lack of these biologic markers endocrine therapy and HER2-directed therapies are not recommended in the treatment of TNBC [18] [19] [20] .Although the same general principles used in the diagnosis and treatment of non-triple-negative breast cancer generally apply to TNBC, it has a lot of differences in risk factors, molecular and histologic features, clinical behavior and chemotherapy sensitivity [2] [3] [4] [5] [6] .TNBC defines a heterogeneous mix of breast tumors [7] . TNBC generally has a poorer prognosis among patients with breast cancer [21] .
ER, PR and HER2 are the important biologic markers used in targeted treatment of breast cancer [22] .
Understanding of other biological characteristics of TNBC, the development of new therapeutical approaches and identification of new markers is necessary due to the lack of biological markers like ER, PR and HER2.CD44+, CD24-/low and ALDH1+ are the most consistently used biomarkers to identify the breast cancer stem cell groups [16] [17] .The clinical importance of ALDH1 in TNBC is a less investigated issue. Patients with metastatic disease were followed with a surveillance routine after receiving 3 and 6 cycles of chemotherapy.
Formalin-fixed, paraffin-embedded tissues was cut into 3 µm thick sections, deparaffinided, stained with hematoxylin-eosin and 45.7% of the tumors showed lymphatic invasion whereas 54.3% showed no invasion. 8.7% of the tumors showed perineural invasion whereas 91.3%
showed no invasion. 10.3% of the tumors showed vascular invasion whereas 89.7% showed no invasion. 10.5% of the tumors were multicentric whereas 89.5% were unicentric.Among87 patients, prognostic factors that can affect the therapy choice [9, 11] .
Based on the diagnostic evaluation of suspected breast cancer one of the patients was diagnosed after physical examination, one during routine screening and all others (n:85) were suspected by their self-examination. These findings support the fact that TNBC will more likely present as an 'interval cancer' between two screenings. These findings also show that TNBC screening and diagnosis need to be improved [12] [13] [14] .
In our study 14 
